Open-Label, Single-Arm Phase Ib/Ii Study of Immune Combination Therapy with Belantamab Mafodotin and Elotuzumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - Sep 11, 2026 - Abstract #PA-322; Pres time: Sep 25, 2026; P1/2 | "The combination immune therapy of belantamab mafodotin and elotuzumab appears to have an encouraging safety profile and a promising activity in patients with heavily pretreated RRMM, including in those with prior failure of BCMA-targeted T-cell redirection therapy. Funding and Product for this study was provided by GSK NCT05002816 ."
Clinical • Combination therapy • P1/2 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Ophthalmology • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia
|
|
Sabrina L. Browning1; Fangyong Li2; Terri L. Parker1; Noffar Bar1; Catherine Wei3; Tara Anderson4; Erica Stevens4; Jennifer VanOudenhove5; Martin Matthews5; Elan Gorshein1; Jason Haldas6; Ashita Talsani7; Stuart Seropian7; Kert Sabbath8; Stephanie Halene7; Natalia Neparidze1
|